RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery... Show more
Industry MedicalNursingServices
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MLAAX | 9.04 | 0.09 | +1.01% |
| NYLIM Winslow Large Cap Growth Class A | |||
| GXXAX | 12.69 | N/A | N/A |
| abrdn US Sustainable Leaders A | |||
| PAGLX | 48.86 | N/A | N/A |
| T. Rowe Price Global Growth Stock Adv | |||
| MIGPX | 18.70 | N/A | N/A |
| Morgan Stanley Inst Global Insgt A | |||
| FGKMX | 140.15 | N/A | N/A |
| Fidelity Advisor Communication ServicesZ | |||
A.I.dvisor indicates that over the last year, RXST has been loosely correlated with DCTH. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if RXST jumps, then DCTH could also see price increases.
| Ticker / NAME | Correlation To RXST | 1D Price Change % | ||
|---|---|---|---|---|
| RXST | 100% | +1.01% | ||
| DCTH - RXST | 33% Loosely correlated | +0.70% | ||
| AZTA - RXST | 28% Poorly correlated | +2.22% | ||
| TNDM - RXST | 28% Poorly correlated | -6.55% | ||
| BBLG - RXST | 28% Poorly correlated | -1.82% | ||
| GKOS - RXST | 28% Poorly correlated | -1.84% | ||
More | ||||
| Ticker / NAME | Correlation To RXST | 1D Price Change % |
|---|---|---|
| RXST | 100% | +1.01% |
| Medical/Nursing Services industry (141 stocks) | 2% Poorly correlated | +0.38% |
| Health Services industry (242 stocks) | 2% Poorly correlated | +0.38% |
RXST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 42 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.
The 10-day RSI Indicator for RXST moved out of overbought territory on September 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 17 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXST as a result. In 77 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
RXST moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
RXST broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXST advanced for three days, in 230 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 199 of 224 cases where RXST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.950) is normal, around the industry mean (10.685). P/E Ratio (0.000) is within average values for comparable stocks, (67.907). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.653). RXST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (1.944) is also within normal values, averaging (35.925).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. RXST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.